Grace Colon - 01 Jan 2023 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Role: Director
Signature: /s/ Robert Hesslein, as Attorney-in-Fact for Grace Colon
Issuer symbol: VYGR
Transactions as of: 01 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 04 Jan 2023, 15:55:10 UTC
Previous filing: 11 Aug 2022
Next filing: 07 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VYGR	Stock Option (Right to Buy)	Award	$0	+44,000		$0.000000	44,000	01 Jan 2023	Common Stock	44,000	$6.10	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/16th of the shares of common stock underlying the option vesting upon the three-month anniversary of the Vesting Commencement Date and an additional 1/16th of the shares of common stock underlying the option vesting at the end of each successive three-month period thereafter, subject to the Reporting Person's continued service as a director.

Content

This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/16th of the shares of common stock underlying the option vesting upon the three-month anniversary of the Vesting Commencement Date and an additional 1/16th of the shares of common stock underlying the option vesting at the end of each successive three-month period thereafter, subject to the Reporting Person's continued service as a director.